Chiasma

Company Overview

Snapshot

Founded in April 2001, Chiasma operated with 11–50 employees. The company raised a total of $293.7 million across 10 funding rounds from 12 investors. A significant milestone for Chiasma was its acquisition by Amryt Pharma Group in August 2021.

Business overview

Chiasma was a clinical late-stage biopharmaceutical company focused on developing oral medications for rare and debilitating diseases. Utilizing its Transient Permeability Enhancer (TPE) technology platform, the company aimed to convert injectable proteins, peptides, and small molecule drugs into oral delivery forms. Chiasma's core product, MYCAPSSA (octreotide) capsules, received FDA approval for the long-term maintenance treatment of acromegaly, addressing a market need for oral alternatives to injections. The company operated within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In August 2021, Chiasma was acquired by Amryt Pharma Group, a global biopharmaceutical company specializing in rare diseases. This acquisition marked a strategic exit for Chiasma, integrating its oral therapeutic solutions, including the FDA-approved MYCAPSSA, into Amryt's portfolio. The event signals a validation of Chiasma's TPE technology and its potential to improve treatment options for patients with rare conditions, while also indicating consolidation within the rare disease therapeutics market.

Company Intelligence Q&A

What was the most significant recent corporate event for Chiasma?

Chiasma was acquired by Amryt Pharma Group in August 2021. This acquisition led to Chiasma's delisting from NASDAQ.

When did Chiasma receive FDA approval for MYCAPSSA?

Chiasma received FDA approval for its MYCAPSSA (octreotide) capsules for long-term maintenance treatment in patients with acromegaly in June 2020.

What was the outcome of Chiasma's Phase III acromegaly trial?

In July 2019, Chiasma announced that its Phase III acromegaly trial met all endpoints.

Did Chiasma raise capital through a public offering?

In July 2015, Chiasma raised $102 million in a Nasdaq IPO with a valuation of $562 million.

Which investors participated in Chiasma's Series C funding round in November 2006?

In November 2006, Chiasma received funding from investors including F2 Ventures.